Insulet Corp
PODD289.620USD
-3.260-1.11%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.37BMarket Cap
82.66P/E TTM
More Details of Insulet Corp Company
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Insulet Corp Info
Ticker SymbolPODD
Company nameInsulet Corp
IPO dateMay 15, 2007
CEOMcevoy (Ashley)
Number of employees3900
Security typeOrdinary Share
Fiscal year-endMay 15
Address100 Nagog Park
CityACTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01720-3440
Phone19786007000
Websitehttps://www.omnipod.com
Ticker SymbolPODD
IPO dateMay 15, 2007
CEOMcevoy (Ashley)
Company Executives of Insulet Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-8.50%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-28.94%
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Independent Director
Independent Director
3.85K
+33.25%
Ms. Laetitia Cousin
Ms. Laetitia Cousin
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
3.58K
--
Mr. Prem Singh
Mr. Prem Singh
Senior Vice President - Global Operations
Senior Vice President - Global Operations
3.56K
-16.16%
Dr. Luciana Borio, M.D.
Dr. Luciana Borio, M.D.
Independent Director
Independent Director
3.09K
-13.48%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-8.50%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-28.94%
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
By BusinessUSD
Name
Revenue
Proportion
U.S.Omnipod
453.20M
69.82%
International Omnipod
185.80M
28.62%
Drug Delivery
10.20M
1.57%
By RegionUSD
Name
Revenue
Proportion
United States
463.30M
71.38%
All Other
185.80M
28.62%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
U.S.Omnipod
453.20M
69.82%
International Omnipod
185.80M
28.62%
Drug Delivery
10.20M
1.57%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.46%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Other
60.56%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.46%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Other
60.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
64.92%
Investment Advisor/Hedge Fund
23.48%
Hedge Fund
4.88%
Pension Fund
2.61%
Research Firm
2.52%
Sovereign Wealth Fund
1.57%
Bank and Trust
1.22%
Individual Investor
0.30%
Family Office
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1546
72.07M
102.39%
-3.66M
2025Q2
1541
72.80M
103.47%
-3.81M
2025Q1
1569
72.82M
103.50%
-3.52M
2024Q4
1508
72.57M
103.34%
-4.94M
2024Q3
1436
73.14M
104.31%
-3.15M
2024Q2
1408
72.17M
103.04%
-3.02M
2024Q1
1350
71.60M
102.26%
-3.12M
2023Q4
1320
72.91M
104.42%
-1.52M
2023Q3
1254
72.05M
103.19%
-4.06M
2023Q2
1223
73.42M
105.35%
-3.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.68M
12.33%
+38.89K
+0.45%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.86M
9.74%
-271.19K
-3.80%
Jun 30, 2025
Capital Research Global Investors
4.74M
6.73%
-1.34M
-22.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
6.18%
-13.40K
-0.31%
Jun 30, 2025
State Street Investment Management (US)
3.06M
4.34%
+32.74K
+1.08%
Jun 30, 2025
Baillie Gifford & Co.
2.14M
3.03%
-115.69K
-5.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.74%
+58.31K
+3.12%
Jun 30, 2025
ClearBridge Investments, LLC
1.54M
2.18%
+56.63K
+3.83%
Jun 30, 2025
American Century Investment Management, Inc.
1.31M
1.86%
+157.07K
+13.63%
Jun 30, 2025
Fidelity International
1.13M
1.61%
-155.38K
-12.09%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Langar Global HealthTech ETF
7.26%
Innovator IBD Breakout Opportunities ETF
4.88%
Global X HealthTech ETF
4.76%
Goldman Sachs Future Health Care Equity ETF
4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.7%
iShares Health Innovation Active ETF
3%
Congress SMid Growth ETF
2.82%
iShares U.S. Medical Devices ETF
2.62%
FT Raymond James Multicap Growth Equity ETF
2.3%
Acruence Active Hedge US Equity ETF
2.27%
View more
Langar Global HealthTech ETF
Proportion7.26%
Innovator IBD Breakout Opportunities ETF
Proportion4.88%
Global X HealthTech ETF
Proportion4.76%
Goldman Sachs Future Health Care Equity ETF
Proportion4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion3.7%
iShares Health Innovation Active ETF
Proportion3%
Congress SMid Growth ETF
Proportion2.82%
iShares U.S. Medical Devices ETF
Proportion2.62%
FT Raymond James Multicap Growth Equity ETF
Proportion2.3%
Acruence Active Hedge US Equity ETF
Proportion2.27%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Insulet Corp?
The top five shareholders of Insulet Corp are:
The Vanguard Group, Inc. holds 8.68M shares, accounting for 12.33% of the total shares.
Fidelity Management & Research Company LLC holds 6.86M shares, accounting for 9.74% of the total shares.
Capital Research Global Investors holds 4.74M shares, accounting for 6.73% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.35M shares, accounting for 6.18% of the total shares.
State Street Investment Management (US) holds 3.06M shares, accounting for 4.34% of the total shares.
The Vanguard Group, Inc. holds 8.68M shares, accounting for 12.33% of the total shares.
Fidelity Management & Research Company LLC holds 6.86M shares, accounting for 9.74% of the total shares.
Capital Research Global Investors holds 4.74M shares, accounting for 6.73% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.35M shares, accounting for 6.18% of the total shares.
State Street Investment Management (US) holds 3.06M shares, accounting for 4.34% of the total shares.
What are the top three shareholder types of Insulet Corp?
The top three shareholder types of Insulet Corp are:
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital Research Global Investors
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital Research Global Investors
How many institutions hold shares of Insulet Corp (PODD)?
As of 2025Q3, 1546 institutions hold shares of Insulet Corp, with a combined market value of approximately 72.07M, accounting for 102.39% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.08%.
What is the biggest source of revenue for Insulet Corp?
In FY2025Q2, the U.S.Omnipod business generated the highest revenue for Insulet Corp, amounting to 453.20M and accounting for 69.82% of total revenue.
